Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Merit Medical Systems Inc. (MMSI) Investors with Significant Losses to Contact Its Attorneys, Securities Fraud Lawsuit Filed

MMSI

SAN FRANCISCO, Dec. 4, 2019 /PRNewswire/ -- Hagens Berman urges Merit Medical Systems, Inc. (NASDAQ: MMSI) investors who have suffered losses in excess of $50,000 to submit their losses now to learn if they qualify to recover compensable damages.  A securities fraud class action has been filed against the company and senior executives. 

Hagens Berman Sobol Shapiro LLP

Class Period:

Feb. 26, 2019 - Oct. 30, 2019

Lead Plaintiff Deadline:

Feb. 3, 2020

Sign Up:

www.hbsslaw.com/investor-fraud/MMSI

Contact An Attorney Now:

MMSI@hbsslaw.com


844-916-0895

Merit Medical Systems (MMSI) Securities Class Action:

The complaint alleges that during the Class Period, Defendants misrepresented and concealed that the integrations of Cianna and Vascular Insights, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule. The Company also provided false financial guidance for fiscal 2019 and 2020, according to the complaint.

The market learned the truth on July 25, 2019, when Merit announced disappointing Q2 2019 financial results and reduced FY 2019 revenue and earnings guidance. In response, the price of Merit shares plummeted $13.84, down 25% and wiping out over $750 million of the Company's market capitalization.

Then, about 3 months later, on October 30, 2019, Merit announced disappointing Q3 2019 financial results, reduced FY 2019 guidance for the second time in 3 months, and withdrew 2020 guidance in its entirety. 

In response, the price of Merit shares declined 33%, wiping out over $530 million of the Company's market capitalization.

"We're focused on investors' losses and proving Merit lied about the successful onboarding of Cianna and Vascular Insights," said Reed Kathrein, the Hagens Berman partner leading the investigation.

Whistleblowers: Persons with non-public information regarding Merit should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email MMSI@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 844-916-0895

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hagens-berman-national-trial-attorneys-encourages-merit-medical-systems-inc-mmsi-investors-with-significant-losses-to-contact-its-attorneys-securities-fraud-lawsuit-filed-300969537.html

SOURCE Hagens Berman Sobol Shapiro LLP



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today